Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on April 20, 2026, regarding a Special Meeting of stockholders held by Jaguar Health, Inc. The filing details the approval of five proposals, including amendments to the Certificate of Incorporation and authorization for potential reverse stock splits.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, or liquidity metrics. The only financial figure disclosed relates to a specific debt instrument:
- Secured Promissory Note: $10,810,000 principal amount issued to Streeterville Capital, LLC (originally issued Nov 12, 2025; amended March 6, 2026).
Material Changes and Corporate Actions
Stockholders approved the following material changes at the Special Meeting:
- Authorized Share Increase: The number of authorized voting common shares increased from 298,000,000 to 500,000,000. The total authorized shares to be issued increased from 352,475,074 to 554,475,074. This amendment became effective immediately upon filing with the Delaware Secretary of State.
- Reverse Stock Split Authorization (First): Stockholders authorized the Board to effect a reverse stock split at a ratio between 1-for-15 and 1-for-150 within one year of approval, without further stockholder vote.
- Reverse Stock Split Authorization (Second): Stockholders authorized a second potential reverse stock split at a ratio between 1-for-15 and 1-for-150, to be executed after the first split (if any) and within one year of approval.
- Debt-to-Equity Conversion: Approval was granted for the issuance of common stock upon exchange of the $10,810,000 Streeterville Note pursuant to Section 3(a)(9) of the Securities Act of 1933.
Voting Results
As of the record date (March 2, 2026), 12,419,277 shares were outstanding. 7,181,767 shares were represented at the meeting. All five proposals were approved.
| Proposal | For Votes | Against Votes | Abstained |
|---|---|---|---|
| 1. Increase Authorized Shares | 6,031,263 | 1,129,451 | 21,053 |
| 2. First Reverse Split Authorization | 6,534,230 | 629,671 | 17,866 |
| 3. Second Reverse Split Authorization | 6,519,022 | 644,867 | 17,878 |
| 4. Streeterville Note Exchange | 4,020,240 | 331,148 | 8,968 |
| 5. Adjournment Authority | 6,119,840 | 1,049,331 | 12,596 |
Outlook, Risks, and Contingencies
Management Commentary: The Board has discretion to determine the exact reverse stock split ratio (1-for-15 to 1-for-150) and the timing of execution within the one-year window. The filing of the Tenth Amendment to the Certificate of Incorporation was completed on April 20, 2026.
Risks and Contingencies: The filing does not explicitly detail new risks, but the authorization of reverse stock splits typically indicates an effort to maintain compliance with Nasdaq listing standards (specifically Rule 5635(d) referenced in Proposal 4). The exchange of the Streeterville Note for equity introduces potential dilution to existing shareholders.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and implementation date once announced by the Board (must be within 1 year of April 20, 2026).
- Monitor the terms of the exchange of the $10.81M Streeterville Note for common stock to assess dilution impact.
- Review the full text of the Tenth Amendment (Exhibit 3.1) for any additional provisions regarding the authorized share increase.
- Check subsequent filings for the actual execution of the reverse stock splits, as the Board has not yet set the specific ratio.